Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: Results from a multicenter study

British Journal of Cancer

Volumn 106, Issue 12, 2012, Pages 2016-2024

  Jakubowska, A ^a   Rozkrut, D ^b   Antoniou, A ^c   Hamann, U ^d   Scott, R J ^e   McGuffog, L ^f   Healy, S ^g   Sinilnikova, O M ^h,i   Rennert, G ^j   Lejbkowicz, F ^j   Flugelman, A ^j   Andrulis, I L ^k   Glendon, G ^k   Ozcelik, H ^k,l   Thomassen, M ^m   Paligo, M ⁿ   Aretini, P ⁿ   Kantala, J ^o   Aroer, B ^o   Von Wachenfeldt, A ^o   Liljegren, A ^o   Loman, N ^p   Herbst, K ^p   Kristoffersson, U ^p   Rosenquist, R ^q   Karlsson, P ^r   Stenmark Askmalm, M ^s   Melin, B ^t   Nathanson, K L ^u   Domchek, S M ^u   Byrski, T ^a   Huzarski, T ^a   Gronwald, J ^a   Menkiszak, J ^a   Cybulski, C ^a   Serrano, P ^a   Osorio, A ^v,bu   Cajal, T R ^w   Tsitlaidou, M ^x   Benitez J ^v   Gilbert, M ^d   Rookus, M ^y   Aalfs, C M ^z   Kluijt, I ^y   Boessenkool Pape, J L ^y   Meijers Heijboer, H E J ^aa   Oosterwijk, J C ^ab   Van Asperen, C J ^ac   Blok, M J ^ad   Nelen, M R ^ae   Van Den Ouweland, A M W ^af   Seynaeve, C ^af   Van Der Luijt, R B ^ag   Devilee, P ^ac   Easton, D F ^f   Peock, S ^f   Frost, D ^f   Platte, R ^f   Ellis, S D ^f   Fineberg, E ^f   Evans, D G ^ah   Lalloo, F ^ah   Eeles, R ^ai   Jacobs, C ^aj   Adlard, J ^ak   Davidson, R ^al   Eccles, D ^am   Cole, T ^an   Cook, J ^ao   Godwin, A ^ap   Bove, B ^aq,ar   Stoppa Lyonnet, D ^as,at,au   Caux Moncoutier, V ^as   Belotti, M ^as   Tirapo, C ^as   Mazoyer, S ⁱ   Barjhoux, L ⁱ   Boutry Kryza, N ^h   Pujol, P ^av,aw   Coupier, I ^av,aw   Peyrat, J P ^ax   Vennin, P ^ax   Muller, D ^ay   Fricker, J P ^ay   Venat Bouvet, L ^az   Johannsson, O Th ^ba,bb   Isaacs, C ^bc   Schmutzler, R ^bd   Wappenschmidt, B ^bd   Meindl, A ^be   Arnold, N ^bf   Varon Mateeva, R ^bg   Niederacher, D ^bh   Sutter, C ^bi   Deissler, H ^bj   Preisler Adams, S ^bk   Simard, J ^bl   Soucy, P ^bl   Durocher, F ^bl   Chenevix Trench, G ^g   Beesley, J ^g   Chen, X ^g,bm   Rebbeck, T ^bn   Couch, F ^bo   Wang, X ^bo   Lindor, N ^bo   Fredericksen, Z ^bo   Pankratz, V S ^bo   Peterlongo, P ^bp,bq   Bonanni, B ^br   Fortuzzi, S ^bq   Peissel, B ^bp   Szabo, C ^bs   Mai, P L ^bt   Loud, J T ^bt   Lubinski, J ^a   more..

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b UNIVERSITY OF SZCZECIN   (Poland)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e UNIVERSITY OF NEWCASTLE   (Australia)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^g QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^h HOSPICES CIVILS DE LYON   (France)

ⁱ UNIVERSITÉ LYON 1   (France)

^j CARMEL MEDICAL CENTER   (Israel)

^k MOUNT SINAI HOSPITAL   (Canada)

^l CANCER CARE ONTARIO   (Canada)

^m ODENSE UNIVERSITY HOSPITAL   (Denmark)

ⁿ UNIVERSITY HOSPITAL OF PISA   (Italy)

^o KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^p LUND UNIVERSITY HOSPITAL   (Sweden)

^q UPPSALA UNIVERSITY   (Sweden)

^r SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^s LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^t UMEÅ UNIVERSITY   (Sweden)

^u UNIVERSITY OF PENNSYLVANIA   (United States)

^v Centro Nacional de Investigaciones Oncológicas   (Spain)

^w HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^x INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^y NETHERLANDS CANCER INSTITUTE   (Netherlands)

^z ACADEMIC MEDICAL CENTER   (Netherlands)

^aa VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^ab UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^ac LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^ad MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^ae RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^af ERASMUS MEDICAL CENTER   (Netherlands)

^ag UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^ah UNIVERSITY OF MANCHESTER   (United Kingdom)

^ai INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^aj GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^ak Yorkshire Regional Genetics Service   (United Kingdom)

^al ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^am UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^an BIRMINGHAM CHILDREN S HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^ao SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

^ap UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^aq FOX CHASE CANCER CENTER   (United States)

^ar FNCLCC   (France)

^as INSTITUT CURIE   (France)

^at INSTITUT CURIE   (France)

^au UNIVERSITÉ PARIS DESCARTES   (France)

^av HÔPITAL ARNAUD DE VILLENEUVE   (France)

^aw CENTRE VAL D AURELLE   (France)

^ax CENTRE OSCAR LAMBRET   (France)

^ay Unité d'Oncogénétique   (France)

^az DUPUYTREN UNIVERSITY HOSPITAL   (France)

^ba LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^bb UNIVERSITY OF ICELAND   (Iceland)

^bc GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^bd UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^be UNIVERSITY OF MUNICH   (Germany)

^bf UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^bg CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^bh UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^bi UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^bj UNIVERSITY HOSPITAL ULM   (Germany)

^bk UNIVERSITY OF MÜNSTER   (Germany)

^bl LAVAL UNIVERSITY   (Canada)

^bm PETER MACCALLUM CANCER CENTRE   (Australia)

^bn UNIVERSITY OF PENNSYLVANIA   (United States)

^bo MAYO CLINIC   (United States)

^bp NATIONAL CANCER INSTITUTE   (Italy)

^bq FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^br EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^bs Mayo Clinic   (United States)

^bt U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

^bu CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

more..

Author keywords

BRCA1 2 mutation carriers; breast ovarian cancer risk; MTHFR 677 C>T polymorphism; PHB 1630 C>T polymorphism

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BRCA1 PROTEIN; BRCA2 PROTEIN; PROHIBITIN;

ADULT; ALLELE; ARTICLE; BREAST CANCER; CANCER RISK; DELETION MUTANT; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOMIC INSTABILITY; GENOTYPE; HEREDITY; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; RISK ASSESSMENT;

BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MUTATION; OVARIAN NEOPLASMS; POLYMORPHISM, GENETIC; REPRESSOR PROTEINS; RISK;

EID: 84862017252     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.160     Document Type: Article

References (35)

1. Antoniou AC, Sinilnikova OM, Simard J, Léoné M, Dumont M, Neuhausen SL, Struewing JP, Stoppa-Lyonnet D, Barjhoux L, Hughes DJ, Coupier I, Belotti M, Lasset C, Bonadona V, Bignon YJ, Genetic Modifiers of Cancer Risk in BRCA1/2 Mutation Carriers Study (GEMO), Rebbeck TR, Wagner T, Lynch HT, Domchek SM, Nathanson KL, Garber JE, Weitzel J, Narod SA, Tomlinson G, Olopade OI, Godwin A, Isaacs C, Jakubowska A, Lubinski J, Gronwald J, Górski B, Byrski T, Huzarski T, Peock S, Cook M, Baynes C, Murray A, Rogers M, Daly PA, Dorkins H. Epidemiological Study of BRCA1 and BRCA2 Mutation Carriers (EMBRACE), Schmutzler RK, Versmold B, Engel C, Meindl A, Arnold N, Niederacher D, Deissler H, German Consortium for Hereditary Breast and Ovarian Cancer (GCHBOC), Spurdle AB, Chen X, Waddell N, Cloonan N, Kathleen Cuningham Consortium for Research into Familial Breast Cancer (kConFab), Kirchhoff T, Offit K, Friedman E, Kaufmann B, Laitman Y, Galore G, Rennert G, Lejbkowicz F, Raskin L, Andrulis IL, Ilyushik E, Ozcelik H, Devilee P, Vreeswijk MP, Greene MH, Prindiville SA, Osorio A, Benitez J, Zikan M, Szabo CI, Kilpivaara O, Nevanlinna H, Hamann U, Durocher F, Arason A, Couch FJ, Easton DF, Chenevix-Trench G, Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) (2007) RAD51 135G-4C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet 81: 1186-1200 (Pubitemid 350211449)
2. Antoniou AC, Cunningham AP, Peto J, Evans DG, Lalloo F, Narod SA, Risch HA, Eyfjord JE, Hopper JL, Southey MC, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tryggvadottir L, Syrjakoski K, Kallioniemi OP, Eerola H, Nevanlinna H, Pharoah PD, Easton DF (2008) The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer 98: 1457-1466 (Pubitemid 351543573)
3. Antoniou AC, Wang X, Fredericksen ZS, McGuffog L, Tarrell R, Sinilnikova OM, Healey S, Morrison J, Kartsonaki C, Lesnick T, Ghoussaini M, Barrowdale D, EMBRACE, Peock S, Cook M, Oliver C, Frost D, Eccles D, Evans DG, Eeles R, Izatt L, Chu C, Douglas F, Paterson J, Stoppa-Lyonnet D, Houdayer C, Mazoyer S, Giraud S, Lasset C, Remenieras A, Caron O, Hardouin A, Berthet P, GEMO Study Collaborators, Hogervorst FB, Rookus MA, Jager A, van den Ouweland A, Hoogerbrugge N, van der Luijt RB, Meijers-Heijboer H, Gómez Garća EB, HEBON, Devilee P, Vreeswijk MP, Lubinski J, Jakubowska A, Gronwald J, Huzarski T, Byrski T, Górski B, Cybulski C, Spurdle AB, Holland H, kConFab, Goldgar DE, John EM, Hopper JL, Southey M, Buys SS, Daly MB, Terry MB, Schmutzler RK, Wappenschmidt B, Engel C, Meindl A, Preisler-Adams S, Arnold N, Niederacher D, Sutter C, Domchek SM, Nathanson KL, Rebbeck T, Blum JL, Piedmonte M, Rodriguez GC, Wakeley K, Boggess JF, Basil J, Blank SV, Friedman E, Kaufman B, Laitman Y, Milgrom R, Andrulis IL, Glendon G, Ozcelik H, Kirchhoff T, Vijai J, Gaudet MM, Altshuler D, Guiducci C, SWE-BRCA, Loman N, Harbst K, Rantala J, Ehrencrona H, Gerdes AM, Thomassen M, Sunde L, Peterlongo P, Manoukian S, Bonanni B, Viel A, Radice P, Caldes T, de la Hoya M, Singer CF, Fink-Retter A, Greene MH, Mai PL, Loud JT, Guidugli L, Lindor NM, Hansen TV, Nielsen FC, Blanco I, Lazaro C, Garber J, Ramus SJ, Gayther SA, Phelan C, Narod S, Szabo CI, MOD SQUAD, Benitez J, Osorio A, Nevanlinna H, Heikkinen T, Caligo MA, Beattie MS, Hamann U, Godwin AK, Montagna M, Casella C, Neuhausen SL, Karlan BY, Tung N, Toland AE, Weitzel J, Olopade O, Simard J, Soucy P, Rubinstein WS, Arason A, Rennert G, Martin NG, Montgomery GW, Chang-Claude J, Flesch-Janys D, Brauch H, GENICA, Severi G, Baglietto L, Cox A, Cross SS, Miron P, Gerty SM, Tapper W, Yannoukakos D, Fountzilas G, Fasching PA, Beckmann MW, Dos Santos Silva I, Peto J, Lambrechts D, Paridaens R, Rüdiger T, Försti A, Winqvist R, Pylkäs K, Diasio RB, Lee AM, Eckel-Passow J, Vachon C, Blows F, Driver K, Dunning A, Pharoah PP, Offit K, Pankratz VS, Hakonarson H, Chenevix-Trench G, Easton DF, Couch FJ (2010) A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet 42: 885-892
4. Bagley PJ, Selhub J (1998) A common mutation in the methylenetetrahydrofolate reductase gene is associated with an accumulation of formylated tetrahydrofolates in red blood cells. Proc Natl Acad Sci USA 95: 13217-13220 (Pubitemid 28509551)
5. Barnes DR, Lee A, EMBRACE Investigators, kConFab Investigators, Easton DF, Antoniou AC (2012) Evaluation of association methods for analysing modifiers of disease risk in carriers of high-risk mutations. Genet Epidemiol 36: 274-291
6. Beetstra S, Suthers G, Dhillon V, Salisbury C, Turner J, Altree M, McKinnon R, Fenech M (2008) Methionine-dependence phenotype in the de novo pathway in BRCA1 and BRCA2 mutation carriers with and without breast cancer. Cancer Epidemiol Biomarkers Prev 17: 2565-2571
7. Black DM, Nicolai H, Borrow J, Solomon E (1993) A somatic cell hybrid map of the long arm of human chromosome 17, containing the familial breast cancer locus (BRCA1). Am J Hum Genet 52: 702-710 (Pubitemid 23310136)
8. Boos DD (1992) On Generalised score tests. American Statistician 46: 327-333
9. Chenevix-Trench G, Milne RL, Antoniou AC, Couch FJ, Easton DF, Goldgar DE (2007) An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA). Breast Cancer Res 9: 104
10. Choi SW, Mason JB (2002) Folate status: effects on pathways of colorectal carcinogenesis. J Nutr 132: 2413S-2418S (Pubitemid 34848118)
11. Friso S, Choi SW, Girelli D, Mason JB, Dolnikowski GG, Bagley PJ, Olivieri O, Jacques PF, Rosenberg IH, Corrocher R, Selhub J (2002) A common mutation in the 5,10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status. Proc Natl Acad Sci USA 99: 5606-5611 (Pubitemid 34411596)
12. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluijtmans LA, van den Heuvel LP (1995) A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10: 111-113
13. Gershoni-Baruch R, Dagan E, Israeli D, Kasinetz L, Kadouri E, Friedman E (2000) Association of the C677T polymorphism in the MTHFR gene with breast and/or ovarian cancer risk in Jewish women. Eur J Cancer 36: 2313-2316
14. Goldgar DE, Easton DF, Deffenbaugh AM, Monteiro AN, Tavtigian SV, Couch FJ (2004) Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. Am J Hum Genet 75: 535-544 (Pubitemid 39244769)
15. Jakubowska A, Gronwald J, Górski B, Huzarski T, Byrski T, Benner A, Lubiński J, Scott RJ, Hamann U (2007a) The 3' untranslated region C4T polymorphism of prohibitin is a breast cancer risk modifier in Polish women carrying a BRCA1 mutation. Breast Cancer Res Treat 104: 67-74 (Pubitemid 46976630)
16. Jakubowska A, Gronwald J, Menkiszak J, Górski B, Huzarski T, Byrski T, Edler L, Lubiński J, Scott RJ, Hamann U (2007b) Methylenetetrahydrofolate reductase polymorphisms modify BRCA1-associated breast and ovarian cancer risks. Breast Cancer Res Treat 104: 299-308 (Pubitemid 47231276)
17. Jupe ER, Badgett AA, Neas BR, Craft MA, Mitchell DS, Resta R, Mulvihill JJ, Aston CE, Thompson LF (2001) Single nucleotide polymorphism in prohibitin 39 untranslated region and breast-cancer susceptibility. Lancet 357: 1588-1589 (Pubitemid 32488819)
18. Jupe ER, Liu XT, Kiehlbauch JL, McClung JK, Dell'Orco RT (1996a) The 3' untranslated region of prohibitin and cellular immortalization. Exp Cell Res 224: 128-135
19. Jupe ER, Liu XT, Kiehlbauch JL, McClung JK, Dell'Orco RT (1996b) Prohibitin in breast cancer cell lines: loss of antiproliferative activity is linked to 3 untranslated region mutations. Cell Growth Differ 7: 871-878 (Pubitemid 26360726)
20. Kim YI (1999) Folate and carcinogenesis: evidence, mechanisms, and implications. J Nutr Biochem 10: 66-88
21. Macis D, Maisonneuve P, Johansson H, Bonanni B, Botteri E, Iodice S, Santillo B, Penco S, Gucciardo G, D'Aiuto G, Rosselli Del Turco M, Amadori M, Costa A, Decensi A (2007) Methylenetetrahydrofolate reductase (MTHFR) and breast cancer risk: a nested-case-control study and a pooled meta-analysis. Breast Cancer Res Treat 106: 263-271 (Pubitemid 350045014)
22. Manjeshwar S, Branam DE, Lerner MR, Brackett DJ, Jupe ER (2003) Tumor suppression by the prohibitin gene 30 untranslated region RNA in human breast cancer. Cancer Res 63: 5251-5256 (Pubitemid 37139838)
23. Manjeshwar S, Lerner MR, Zang XP, Branam DE, Pento JT, Lane MM, Lightfoot SA, Brackett DJ, Jupe ER (2004) Expression of prohibitin 3' untranslated region suppressor RNA alters morphology and inhibits motility of breast cancer cells. J Mol Histol 35: 639-646 (Pubitemid 41404650)
24. Nagai MA, Yamamoto L, Salaorni S, Pacheco MM, Brentani MM, Barbosa EM, Brentani RR, Mazoyer S, Smith SA, Ponder BA, Mulligan LM (1994) Detailed deletion mapping of chromosome segment 17q12-21 in sporadic breast tumours. Genes Chromosomes Cancer 11: 58-62 (Pubitemid 24273974)
25. Nass SJ, Herman JG, Gabrielson E, Iversen PW, Parl FF, Davidson NE, Graff JR (2000) Aberrant methylation of the estrogen receptor and E-cadherin 5' CpG islands increases with malignant progression in human breast cancer. Cancer Res 60: 4346-4348 (Pubitemid 32103608)
26. Pepe C, Guidugli L, Sensi E, Aretini P, D'Andrea E, Montagna M, Manoukian S, Ottini L, Radice P, Viel A, Bevilacqua G, Caligo MA (2007) Methyl group metabolism gene polymorphisms as modifier of breast cancer risk in Italian BRCA1/2 carriers. Breast Cancer Res Treat 103: 29-36 (Pubitemid 46653264)
27. Qi X, Ma X, Yang X, Fan L, Zhang Y, Zhang F, Chen L, Zhou Y, Jiang J (2010) Methylenetetrahydrofolate reductase polymorphisms and breast cancer risk: a meta-analysis from 41 studies with 16, 480 cases and 22 388 controls. Breast Cancer Res Treat 123: 499-506
28. Ramus SJ, Kartsonaki C, Gayther SA, Pharoah PD, Sinilnikova OM, Beesley J, Chen X, McGuffog L, Healey S, Couch FJ, Wang X, Fredericksen Z, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Roversi G, Barile M, Viel A, Allavena A, Ottini L, Papi L, Gismondi V, Capra F, Radice P, Greene MH, Mai PL, Andrulis IL, Glendon G, Ozcelik H, OCGN, Thomassen M, Gerdes AM, Kruse TA, Cruger D, Jensen UB, Caligo MA, Olsson H, Kristoffersson U, Lindblom A, Arver B, Karlsson P, Stenmark Askmalm M, Borg A, Neuhausen SL, Ding YC, Nathanson KL, Domchek SM, Jakubowska A, Lubinski J, Huzarski T, Byrski T, Gronwald J, Górski B, Cybulski C, Debniak T, Osorio A, Durán M, Tejada MI, Beńtez J, Hamann U, Rookus MA, Verhoef S, Tilanus-Linthorst MA, Vreeswijk MP, Bodmer D, Ausems MG, van Os TA, Asperen CJ, Blok MJ, Meijers-Heijboer HE, HEBON, EMBRACE, Peock S, Cook M, Oliver C, Frost D, Dunning AM, Evans DG, Eeles R, Pichert G, Cole T, Hodgson S, Brewer C, Morrison PJ, Porteous M, Kennedy MJ, Rogers MT, Side LE, Donaldson A, Gregory H, Godwin A, Stoppa-Lyonnet D, Moncoutier V, Castera L, Mazoyer S, Barjhoux L, Bonadona V, Leroux D, Faivre L, Lidereau R, Nogues C, Bignon YJ, Prieur F, Collonge-Rame MA, Venat-Bouvet L, Fert-Ferrer S, GEMO Study Collaborators, Miron A, Buys SS, Hopper JL, Daly MB, John EM, Terry MB, Goldgar D, BCFR, Hansen TV, Jønson L, Ejlertsen B, Agnarsson BA, Offit K, Kirchhoff T, Vijai J, Dutra-Clarke AV, Przybylo JA, Montagna M, Casella C, Imyanitov EN, Janavicius R, Blanco I, Lázaro C, Moysich KB, Karlan BY, Gross J, Beattie MS, Schmutzler R, Wappenschmidt B, Meindl A, Ruehl I, Fiebig B, Sutter C, Arnold N, Deissler H, Varon-Mateeva R, Kast K, Niederacher D, Gadzicki D, Caldes T, de la Hoya M, Nevanlinna H, Aittomäki K, Simard J, Soucy P, kConFab Investigators, Spurdle AB, Holland H, Chenevix-Trench G, Easton DF, Antoniou AC (2011) Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 103: 105-116
29. Roskams AJ, Friedman V, Wood CM, Walker L, Owens GA, Stewart DA, Altus MS, Danner DB, Liu XT, McClung JK (1993) Cell cycle activity and expression of prohibitin mRNA. J Cell Physiol 157: 289-295 (Pubitemid 23332772)
30. Soares J, Pinto AE, Cunha CV, André S, Barão I, Sousa JM, Cravo M (1999) Global DNA hypomethylation in breast carcinoma: correlation with prognostic factors and tumor progression. Cancer 85: 112-118 (Pubitemid 29031364)
31. Wang S, Nath N, Adlam M, Chellappan S (1999) Prohibitin, a potential tumor suppressor, interacts with RB and regulates E2F function. Oncogene 18: 3501-3510 (Pubitemid 29317345)
32. Weisberg I, Tran P, Christensen B, Sibani S, Rozen R (1998) A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 64: 169-172 (Pubitemid 28453294)
33. Weisberg IS, Jacques PF, Selhub J, Bostom AG, Chen Z, Curtis ER, Eckfeldt JH, Rozen R (2001) The 1298A-4C polymorphism in methylenetetrahydrofolate reductase (MTHFR): in vitro expression and association with homocysteine. Atherosclerosis 156: 409-415 (Pubitemid 32522922)
34. White JJ, Ledbetter DH, Eddy Jr RL, Shows TB, Stewart DA, Nuell MJ, Friedman V, Wood CM, Owens GA, McClung JK, Danner DB, Morton CC (1991) Assignment of the human prohibition (sic) gene (PHB) to chromosome 17 and identification of a DNA polymorphism. Genomics 11: 228-230
35. Zhang J, Qiu LX, Wang ZH, Wu XH, Liu XJ, Wang BY, Hu XC (2010) MTHFR C677T polymorphism associated with breast cancer susceptibility: a meta-analysis involving 15 260 cases and 20 411 controls. Breast Cancer Res Treat 123: 549-555